New developments in the treatment of viral respiratory tract infections.
Most respiratory tract infections are viral in origin, yet until recently only a few effective therapies had been developed. This reflected the large number of causative agents and the generally benign course of most infections. However, increasing numbers of serious respiratory infections have been seen in recent years, due to the rising prevalence of immunodeficient patients and the emergence of previously unrecognised pathogens. Better understanding of viral structure, and novel methods of drug design and discovery are leading to the development of potentially valuable new treatments, particularly for influenza and respiratory syncytial virus infection.
European Medical Affairs Department, Bayer Pharma, Stoke Court, Stoke Poges, SL2 4LY, UK.
N J
NJ
Snell